GlassScriptPhysician profile
Taylor N Fiveash
NPI 1962922427
$6,080.19
in general payments reported to CMS, 2019-2025
22 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $925 · 2023: $4,546 · 2024: $125 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,939 · Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,938.93 |
| Food and Beverage | $1,910.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,199.80 | 2022-2023 | |
| Medtronic, INC. | $1,942.57 | 2021-2023 | Micra, Reveal Linq |
| Novo Nordisk INC | $206.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $199.85 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $191.35 | 2023-2025 | Watchman Access System, Watchman Flx, General - Crm_crm |
| Astrazeneca Pharmaceuticals LP | $185.56 | 2021-2023 | Andexxa, Farxiga |
| Abbvie INC. | $178.55 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $149.22 | 2022-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.78 | 2022-2023 | Lifevest |
| Lilly USA, LLC | $105.56 | 2022 | |
| Merck Sharp & Dohme LLC | $98.03 | 2021-2023 | Verquvo |
| Amgen INC. | $89.68 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.35 | 2022-2023 | Jardiance |
| Ironshore Pharmaceuticals INC. | $78.13 | 2022 | |
| Pfizer INC. | $62.93 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.15 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $33.75 | 2023-2025 | Onpattro, Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $29.91 | 2025 | |
| Genentech USA, INC. | $20.68 | 2023 | Ocrevus |
| Glaxosmithkline, LLC. | $18.56 | 2022 | |
| Vital Connect, INC | $12.06 | 2022 | |
| Esperion Therapeutics, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Fiveash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.